Nasdaq · Biotech stocks database
IKT (Inhibikase Therapeutics Inc.) stock: $1.50, $209.3M market cap, $159.0M cash, $50.3M EV, $464.6M fully diluted market cap. Next expected readout: Jun-29. Lead program: IKT-001 (Pulmonary Arterial Hypertension), Phase 3. Data from Fully Diluted's biotech stocks database.
Our lead product candidate is IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005.
Source: 10-K FY2025 via SEC EDGAR
| Cash | $159.0M |
|---|---|
| Debt | $0.0M |
| Net cash | $159.0M |
| Enterprise value | $50.3M |
| Basic shares | 139.0M shares |
| Fully diluted shares | 309.7M shares |
| Fully diluted market cap | $464.6M |
| Cash per share | $1.14 |
| Quarterly burn | $12.4M |
| Cash runway | 12.8 quarters |
Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.
Cap table as of 2026-08-04.
Loading IKT daily closes…
IKT-001 · Jul 13 - Aug 24 in 33 mo · Phase 3 · Pulmonary Arterial Hypertension